BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
SHANGHAI, March 13, 2025 /PRNewswire/ — BioCity Biopharmaceutics Co., Ltd., a clinical-stage…